Senescent Cells Drive Precancer: A Double-Edged Sword in Early Tumor Biology

Cancer research has historically focused on advanced disease, but the precancerous state—when tissues are molecularly altered yet not yet malignant—represents a critical, underexplored window for intervention. This commentary in Cancer Cell synthesizes current evidence on the paradoxical roles of cellular senescence across multiple cell types within the precancer tissue microenvironment (PreTME), providing a framework for precision cancer interception.

Cellular senescence is a stable, largely irreversible cell cycle arrest triggered by telomere shortening, DNA damage, oncogene activation, mitochondrial dysfunction, oxidative stress, and epigenetic alterations. Senescent cells are metabolically active and secrete the senescence-associated secretory phenotype (SASP)—a complex mix of cytokines, growth factors, matrix-remodeling enzymes, extracellular vesicles, lipids, and nucleic acids. Though typically comprising fewer than ~10% of cells even in highly affected tissues, their paracrine influence can be outsized.

In the early/transient phase, epithelial senescence acts as a tumor suppressive barrier. Senescent cells upregulate MHC-I/MHC-II and senescence-associated antigens, release DAMPs (e.g., ATP, calreticulin), and secrete SASP factors that recruit NK cells, iNKT cells, neutrophils, macrophages, and CD4+/CD8+ T cells to mediate immune clearance—a process called senescence surveillance. In senescent hepatocytes, CD4+ T cell-dependent adaptive immunity has been shown to orchestrate this clearance. When this clearance fails—due to aging or immune dysfunction—senescent cells accumulate and transition to a chronic state. Persistent SASP then tips the balance toward a proinflammatory, protumorigenic PreTME, partly through cytoplasmic chromatin fragments (CCFs) activating the cGAS-STING pathway, sustaining inflammatory cytokine production and creating a feedforward loop in neighboring stromal and immune cells.

The commentary expands the traditionally epithelial-centric view of senescence to cover the stromal and immune compartments. Senescent fibroblasts secrete SASP factors—most notably GDF15, which activates ERK, p38, and AKT signaling—and remodel the extracellular matrix to drive proliferation, migration, and invasion of premalignant epithelial cells. They also upregulate HLA-E, engaging NKG2A inhibitory receptors on NK and CD8+ T cells, thereby suppressing immune clearance. Senescent T cells, particularly p16+ memory CD4+ T cells, accumulate with age and in obesity, display exhaustion markers, and produce proinflammatory SASP factors that exacerbate inflammation and metabolic dysfunction. Senescent myeloid cells further reprogram the immune landscape toward immune suppression and pro-tumor states.

For interception, two broad pharmacological classes are highlighted: senolytics (e.g., navitoclax, dasatinib + quercetin, FOXO4-interfering peptides) that selectively eliminate senescent cells by targeting BCL-2 survival pathways; and senomorphics (e.g., metformin, rapamycin/eRAPA) that suppress SASP via NF-κB and mTOR inhibition. Lifestyle strategies including exercise and caloric restriction are noted as complementary, lower-risk approaches. Key challenges include the absence of validated, tissue-specific senescence biomarkers for clinical use, the heterogeneity of SASP across cell types and contexts, and the risk of systemic off-target effects from applying senotherapeutics in preventive settings where senescence may serve reparative roles.